-
Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of its flu vaccines in China following concerns over declining potency identified during routine batch checks. According to FiercePharma.com, which cites an email from a Sanofi spokesperson, the suspension will affect supplies of both Vaxigrip and…
-
Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million
•
Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active pharmaceutical ingredients (APIs) division to Tibet Duo Rui Pharmaceutical Co., Ltd. for RMB 10 million. Following the transaction, the API unit will establish a supply relationship with Frontier, with a separate purchase agreement to be…
-
Johnson & Johnson China’s Cardiovascular and Professional Solutions Division Head, Kevin Chen, Resigns for New Opportunities
•
Johnson & Johnson (J&J, NYSE: JNJ), a leading US multinational conglomerate, has announced the resignation of Kevin Chen from his role as General Manager and Head of External Affairs and Market Access for the Cardiovascular and Professional Solutions division of J&J MedTech in China. Chen is pursuing “external development opportunities,”…
-
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
•
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952), has reported its financial results for the first half of 2024. The firm’s revenues experienced a substantial month-on-month increase of 158%, reaching RMB 302 million for the six-month period, primarily propelled by sales of the…
-
JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication
•
JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2126), has received additional indication approval from the National Medical Products Administration (NMPA) for its chimeric antigen receptor (CAR) T cell therapy, Carteyva (relmacabtagene autoleucel injection). This approval extends to adult patients with…
-
Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions
•
ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT CELL, which is derived from mesenchymal stem cells exosomes. One study aims to evaluate the product’s efficacy in treating cough symptoms following infection, while the other is focused on safety and preliminary efficacy in the…
-
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has reported its financial results for the first half of 2024. The Chinese pharmaceutical giant recorded an operating revenue of RMB 20.463 billion, reflecting a 5.31% year-on-year increase,…
-
Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology
•
Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered into a strategic partnership with SPH RD, a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd focused on rare diseases and pediatrics. The collaboration centers around BDgene’s innovative BDlendi insulator technology, which is slated for the…
